GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path
This article was originally published in Pharmaceutical Approvals Monthly
Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.
You may also be interested in...
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
On the rebound after venous embolisms led to a clinical hold, Capesaris is getting good results at a significantly lower dose than what was used in that fated trial, and GTx is betting the novel estrogen receptor agonist can improve on the efficacy of androgen deprivation therapy while ameliorating its symptoms.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.